Group 1 - The company is currently advancing a private placement to raise funds not exceeding 708.96 million yuan, aimed at acquiring 68.59% equity in Hubei Hongyi Chemical Technology Co., Ltd. [5] - The company has completed the audit and evaluation of the equity of Hongyi Company, signed the equity acquisition agreement, and obtained the necessary approvals from regulatory authorities [5] - As of the date of this report, the private placement has been approved by the Shenzhen Stock Exchange and registered with the China Securities Regulatory Commission, with payments from investors completed and equity transfer executed [5] Group 2 - All directors attended the board meeting that reviewed the report [2] - The board meeting was held on August 25, 2025, via communication voting [6][19] - The board approved several resolutions, including amendments to the company’s articles of association and the establishment of various committee working rules [10][11][12][13] Group 3 - The company did not distribute cash dividends or bonus shares during the reporting period [3] - There were no changes in the controlling shareholder or actual controller during the reporting period [5] - The company’s half-year report and summary were approved by both the board and the supervisory board [25][14] Group 4 - The company aims to optimize its governance mechanism and improve operational standards through amendments to its articles of association [27] - The amendments are in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [27]